Stocks
CONMED Financial Statements (CNMD) |
||||||||||
| CONMEDsmart-lab.ru | % | 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 22.02.2021 | 22.02.2022 | 21.02.2023 | 31.12.2023 | 28.02.2024 | 31.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 862.5 | 1 011 | 1 045 | 1 245 | 1 241 | 1 286 | |||
| Operating Income, bln rub | -27.0 | 37.8 | 70.1 | 137.2 | 130.8 | 188.2 | ||||
| EBITDA, bln rub | ? | 113.6 | 158.4 | 7.80 | 209.1 | 182.2 | 228.7 | |||
| Net profit, bln rub | ? | 9.52 | 62.5 | -80.6 | 64.5 | 64.5 | 131.7 | |||
| OCF, bln rub | ? | 64.5 | 111.8 | 33.4 | 143.7 | 125.3 | 180.0 | |||
| CAPEX, bln rub | ? | 13.0 | 14.9 | 21.8 | 0.000 | 19.0 | 13.9 | |||
| FCF, bln rub | ? | 51.5 | 96.9 | 11.6 | 143.7 | 106.3 | 166.1 | |||
| Dividend payout, bln rub | 22.8 | 23.3 | 24.0 | 0.000 | 24.5 | 24.6 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 239.8% | 37.2% | 0.00% | 0.00% | 38.0% | 18.7% | ||||
| OPEX, bln rub | 414.3 | 458.3 | 501.2 | 549.7 | 564.2 | 510.3 | ||||
| Cost of production, bln rub | 402.2 | 442.6 | 474.2 | 557.8 | 597.9 | 587.7 | ||||
| R&D, bln rub | 40.5 | 43.6 | 47.2 | 52.6 | 52.6 | 55.3 | ||||
| Interest expenses, bln rub | 44.1 | 35.5 | 28.9 | 39.8 | 39.8 | 37.9 | ||||
| Assets, bln rub | 1 752 | 1 766 | 2 298 | 0.000 | 2 300 | 2 316 | ||||
| Net Assets, bln rub | ? | 709.0 | 785.4 | 745.5 | 0.000 | 834.2 | 932.9 | |||
| Debt, bln rub | 775.9 | 684.7 | 1 055 | 0.000 | 991.3 | 940.8 | ||||
| Cash, bln rub | 27.4 | 20.8 | 28.9 | 0.000 | 24.3 | 38.5 | ||||
| Net debt, bln rub | 748.5 | 663.8 | 1 026 | 0.00 | 967.0 | 902.3 | ||||
| Ordinary share price, rub | 112.0 | 141.8 | 88.6 | 109.5 | 109.5 | 95.0 | ||||
| Number of ordinary shares, mln | 28.6 | 29.2 | 30.0 | 31.5 | 30.7 | 30.9 | ||||
| Market cap, bln rub | 3 201 | 4 134 | 2 663 | 3 455 | 3 358 | 2 932 | ||||
| EV, bln rub | ? | 3 950 | 4 798 | 3 689 | 3 455 | 4 325 | 3 835 | |||
| Book value, bln rub | -411 | -303 | -752 | 0 | -622 | -500 | ||||
| EPS, rub | ? | 0.33 | 2.14 | -2.68 | 2.04 | 2.10 | 4.27 | |||
| FCF/share, rub | 1.80 | 3.32 | 0.39 | 4.56 | 3.47 | 5.38 | ||||
| BV/share, rub | -14.4 | -10.4 | -25.0 | 0.00 | -20.3 | -16.2 | ||||
| EBITDA margin, % | ? | 13.2% | 15.7% | 0.75% | 16.8% | 14.7% | 17.8% | |||
| Net margin, % | ? | 1.10% | 6.19% | -7.71% | 5.18% | 5.19% | 10.2% | |||
| FCF yield, % | ? | 1.61% | 2.34% | 0.43% | 4.16% | 3.17% | 5.67% | |||
| ROE, % | ? | 1.34% | 7.96% | -10.8% | 7.73% | 14.1% | ||||
| ROA, % | ? | 0.54% | 3.54% | -3.51% | 2.80% | 5.69% | ||||
| P/E | ? | 336.4 | 66.1 | -33.0 | 53.6 | 52.1 | 22.3 | |||
| P/FCF | 62.1 | 42.7 | 229.9 | 24.0 | 31.6 | 17.7 | ||||
| P/S | ? | 3.71 | 4.09 | 2.55 | 2.78 | 2.71 | 2.28 | |||
| P/BV | ? | -7.79 | -13.6 | -3.54 | -5.40 | -5.87 | ||||
| EV/EBITDA | ? | 34.8 | 30.3 | 473.0 | 16.5 | 23.7 | 16.8 | |||
| Debt/EBITDA | 6.59 | 4.19 | 131.6 | 0.00 | 5.31 | 3.95 | ||||
| R&D/CAPEX, % | 311.0% | 293.1% | 216.4% | 276.4% | 397.7% | |||||
| CAPEX/Revenue, % | 1.51% | 1.47% | 2.08% | 0.00% | 1.53% | 1.08% | ||||
| CONMED shareholders | ||||||||||
